Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
AN2 Therapeutics, Inc. is a biopharmaceutical company specializing in novel small molecule therapeutics derived from boron chemistry. Its lead candidate, epetraborole, targets treatment-refractory non-tuberculous mycobacterial lung disease, addressing a significant unmet need. With a focus on infectious diseases and oncology, AN2 is advancing multiple programs, including a partnership with the Bill and Melinda Gates Foundation for tuberculosis and malaria treatments, leveraging non-dilutive funding for global health initiatives.
This description was generated via AI from an annual report. Updated about 1 year ago.